EAM
AVTX icon

Exome Asset Management’s Avalo Therapeutics AVTX Stock Holding History

Exome Asset Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-159,341
Closed -$2.38M – 54
2026
Q1 		$2.38M Buy
+159,341
New +$2.49M 1.23% 35
2025
Q4 		– Sell
-100,036
Closed -$1.27M – 65
2025
Q3 		$1.27M Buy
+100,036
New +$860K 0.77% 47

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Exome Asset Management's AVTX Position: Q2 2026 in Review

Exome Asset Management sold out of Avalo Therapeutics (AVTX) in Q2 2026, closing a stake of 159,341 shares — an estimated $2.38M sold.

Exome Asset Management first reported a position in AVTX in Q3 2025 and held it in 2 quarters. The position peaked at $2.38M in Q1 2026. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Exome Asset Management reported no remaining Avalo Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Exome Asset Management sold 159,341 Avalo Therapeutics shares in Q2 2026, an estimated $2.38M.
  • Exome Asset Management first reported a position in Avalo Therapeutics in Q3 2025 and held it in 2 quarters.
  • Exome Asset Management's Avalo Therapeutics position peaked at $2.38M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.